Xcout Intel
Tubulis competitors & alternatives
The 12 closest competitors and alternatives to Tubulis among biotechnology companies — ranked by similarity to what Tubulis actually does, not by market-cap band.
Subscribe to see Tubulis’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Tubulis
Tubulis is a biotechnology organization headquartered in Munich that generates uniquely matched antibody-drug conjugates with superior biophysical properties.
Tubulis at a glance
Tubulis is a biotechnology company headquartered in Germany. It has raised at least $397.7M across the 3 funding rounds on record. Its most recent funding round, Series C, raised $322.5M in October 2025. Xcout tracks 14 named people at Tubulis, including Dominik Schumacher (CEO and Co-founder).
Tubulis leadership
- Dominik SchumacherCEO and Co-founder
- Dr. Dominik SchumacherCEO
- Dr. Jonas Helma-SmetsCSO
- Dr. Armin WeidmannSenior Vice President Quality
- Dr. Moetaz B. AlbizemSenior Vice President and Head of Clincal Operations
- Dr. Olivier MarcqSenior Vice President CMC
8 more named people on record for Tubulis, with roles, board committees and tenure — see the full roster →
Tubulis funding rounds
At least $397.7M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $322.5M | 13 named | |
| Series B | $63M | 1 named | |
| — | $12.2M | 13 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Tubulis news
Top 12 Tubulis competitors
Ranked by semantic similarity — how close each company is to Tubulis by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Similar biotechnology company
Myricx Bio is a UK biotech company headquartered in London. It specializes in the discovery and development of a novel class of selective cytotoxic payloads for Antibody-Drug Conjugates (ADCs).
Similar biotechnology company
Adcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with supplementary operations in Boston, Massachusetts. The company specializes in the development of innovative antibody-drug conjugates (ADCs) targeting various oncology indications. Its pipeline focuses on delivering best-in-class clinical treatments for patients with high unmet medical needs.
Biotech
AbTx (Antibody for Therapy) is a preclinical-stage biotechnology company headquartered in Dijon, France. The firm designs personalized medicine biotherapies in oncology based on antibody-drug conjugates (ADCs) to treat incurable cancers.
Similar biotechnology company
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Similar biotechnology company
iOmx Therapeutics AG is a biopharmaceutical company located in Martinsried near Munich, Germany, dedicated to discovering and developing next-generation targeted cancer immunotherapies.
Biotech
CrossBridge Bio, Inc. is a medical technology and biopharmaceutical company pioneering an approach to deliver the next generation of stable antibody-drug conjugates (ADCs).
Biotech
Adcytherix is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs) for oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to treat resistant cancers and address unmet medical needs.
Similar biotechnology company
LigaChem Biosciences is a clinical-stage biopharmaceutical company headquartered in Daejeon, South Korea. The company specializes in the discovery and development of novel therapeutics utilizing proprietary technology platforms such as antibody-drug conjugates. With decades of dedicated drug development experience, it drives global healthcare innovation through open collaboration.
Similar biotechnology company
Parabilis Medicines is a biopharmaceutical company that develops ultra-tunable peptide therapeutics utilizing its proprietary Helicon platform. The company focuses on creating novel medicines to target historically undruggable conditions, primarily addressing cancer and other serious diseases with critical medical needs.
Biotech
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Biotech
TILT Biotherapeutics is a Finnish biotechnology company developing tumor-targeted immunotherapies, including oncolytic adenoviruses designed to stimulate immune responses against solid tumors. Its therapies are intended for cancer patients and are developed through clinical and pharmaceutical partnerships.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Tubulis and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Tubulisand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →